![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Japan Tobacco Inc. |
---|---|
Information provided by: | Japan Tobacco Inc. |
ClinicalTrials.gov Identifier: | NCT00686010 |
To demonstrate the effect of JTT-705 doses from 300 mg to 900 mg on the elevation of HDL-C and on the inhibition of CETP activity versus placebo, in patients presenting with mild dyslipidaemia. These objectives will be tested after 4 weeks of treatment.
Condition | Intervention | Phase |
---|---|---|
Type II Hyperlipidaemia |
Drug: Placebo Drug: JTT-705 300mg Drug: JTT-705 600mg Drug: JTT-705 900mg |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A 4-Weeks Treatment, Randomised, Double-Blind, Parallel-Group Study Evaluating The Efficacy and Safety of JTT-705 300 to 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia |
Enrollment: | 198 |
Study Start Date: | May 2000 |
Study Completion Date: | June 2001 |
Primary Completion Date: | January 2001 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Placebo Comparator
Placebo
|
Drug: Placebo
Placebo tablet, 3 tablets, oral, once daily after breakfast
|
2: Experimental
JTT-705 300mg
|
Drug: JTT-705 300mg
JTT-705 tablet, 1 tablet, oral, once daily, after breakfast. Placebo tablet, 2 tablets, oral, once daily, after breakfast.
|
3: Experimental
JTT-705 600mg
|
Drug: JTT-705 600mg
JTT-705 tablet, 2 tablets, oral, once daily, after breakfast. Placebo tablet, 1 tablet, oral, once daily, after breakfast
|
4: Experimental
JTT-705 900mg
|
Drug: JTT-705 900mg
JTT-705 tablet, 3 tablets, oral, once daily, after breakfast
|
Ages Eligible for Study: | 22 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Patients having lipid values as indicated below:
Exclusion Criteria:
Responsible Party: | Japan Tobacco Inc. ( Yukio N, Clinical Research Planning Dept., General Manager ) |
Study ID Numbers: | CAY2-1 |
Study First Received: | May 26, 2008 |
Last Updated: | May 28, 2008 |
ClinicalTrials.gov Identifier: | NCT00686010 |
Health Authority: | Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) |
CETP Inhibitor HDL-C LDL-C Apolipoprotein |
Lipid Metabolism, Inborn Errors Hypercholesterolemia, autosomal dominant Metabolism, Inborn Errors Metabolic Diseases Hyperlipidemias Genetic Diseases, Inborn |
Hyperlipoproteinemia Type II Metabolic disorder Dyslipidemias Hyperlipoproteinemias Lipid Metabolism Disorders |